UCLA Health Department of Medicine, Quality Office
Los Angeles, California, 90095, United States
NCT Number: NCT06277323
This is a prospective randomized clinical trial evaluating how two behaviorally-informed interventions (i.e., monthly report card and storyboard interventions) impact physician behavior, with the goal of closing care gaps in preventive care and disease management.
In particular, the monthly report card intervention seeks to elevate physicians' intentions to close their patients' care gaps, while the storyboard intervention seeks to prompt action by making patients' care gaps salient. The trial investigates the separate and joint impacts of the proposed behaviorally-informed interventions on encouraging physicians to close their patients' care gaps.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Los Angeles, California, 90095, United States
Despite the existence of evidence-based clinical guidelines on how to manage the health of patients with cardiovascular disease that have been shown to improve cardiac function and survival, significant gaps in care persist and optimal medical therapy is often under-utilized. For example, guideline-directed medical therapy (GDMT), statin and aspirin therapy, and blood pressure control are cornerstones of effective management of patients with cardiovascular disease or heart failure. However, current dashboard data indicate that within the UCLA Health system, these medical therapies remain under-utilized.
As part of the quality improvement (QI) initiative sponsored by the Division of Cardiology at UCLA Health, this trial will examine the independent and joint impacts on care gap closure of (1) sending monthly behaviorally-informed emails to physicians with personalized feedback on care gap performance and (2) enhancing the visibility of the open care gaps in the electronic health record upon patient encounter.
Eligible physicians (i.e., UCLA Health Cardiologists) will be randomized to one of four conditions based on a 2 (monthly report card intervention: receive vs. no receive) x 2 (storyboard intervention: receive vs not receive) between-subjects design:
The trial will include physicians participating in an existing UCLA incentive program, as of October 1, 2023, who have a panel size of above 50 patients. In August 2024, new physicians who are eligible for the incentive program and have at least 50 patients in the panel will be randomly assigned into one of the four conditions and become part of the study sample. Randomization will balance for physicians' baseline performance, subspecialty training, years out from training, and estimated panel size.
Monthly performance feedback emails will include physicians' performance on eight cardiology care gaps, their projected earnings in the current quarter and their earnings in the previous quarter. Care gaps include the following: (1) statin or PCSK9 inhibitor use, (2) aspirin use, (3) beta blocker use, (4) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitor use, (5) mineralocorticoid receptor antagonist use, (6) SGLT2i, (7) average HCC/RAF score, and (8) blood pressure control.
Analysis Plan:
Control variables include:
The investigators will conduct subgroup analyses based on:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
Time frame: 6 months after each patient's first encounter with the physician during the first 12 months of the intervention period
Whether a patient completed any of the following seven care gaps will be tracked for each patient who visits a physician during the first 12 months of the intervention period: (1) statin or PCSK9 inhibitor use, (2) aspirin use, (3) beta blocker use, (4) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitor use, (5) mineralocorticoid receptor antagonist use, (6) SGLT2i use, and (7) blood pressure control.
Time frame: 12 months after the intervention starts (for existing patients) or 12 months since patients join the panel (for patients who join during the first six months of the experiment)
Whether a patient completed any of the following seven care gaps will be tracked for each patient who is in a physician's panel during the first six months of the intervention period: (1) statin or PCSK9 inhibitor use, (2) aspirin use, (3) beta blocker use, (4) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitor use, (5) mineralocorticoid receptor antagonist use, (6) SGLT2i use, and (7) blood pressure control.
Time frame: 6 months after each patient's first encounter with the physician during the first 12 months of the intervention period
The number of care gaps closed will be tracked for each patient who visits a physician during the first 12 months of the intervention period, considering the following seven care gaps: (1) statin or PCSK9 inhibitor use, (2) aspirin use, (3) beta blocker use, (4) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitor use, (5) mineralocorticoid receptor antagonist use, (6) SGLT2i use, and (7) blood pressure control. The investigators will also analyze the number of care gaps closed when excluding care gap (7) blood pressure control.
Time frame: 12 months after the intervention starts (for existing patients) or 12 months since patients join the panel (for patients who join during the first six months of the experiment)
The number of care gaps closed will be tracked for each patient who is in a physician's panel during the six months of the intervention period, considering the following seven care gaps: (1) statin or PCSK9 inhibitor use, (2) aspirin use, (3) beta blocker use, (4) angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor-neprilysin inhibitor use, (5) mineralocorticoid receptor antagonist use, (6) SGLT2i use, and (7) blood pressure control. The investigators will also analyze the proportion of care gaps closed when excluding care gap (7) blood pressure control.
Time frame: 12 months after the intervention starts (for existing patients) or 12 months since patients join the panel (for patients who join during the first six months of the experiment)
Whether HCC/RAF coding was completed will be tracked for each patient that is in a physician's panel during the first 12 months of the intervention period.
University of California, Los Angeles
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06155292
Behavioral Economics, Health Maintenance
Los Angeles, California, United States
View Trial DetailsNCT05793788
Cancer, Diabetes
Los Angeles, California, United States
View Trial DetailsNCT05979987
Cancer, Diabetes
Los Angeles, California, United States
View Trial DetailsNCT05791942
Cancer, Diabetes
Los Angeles, California, United States
View Trial Details